You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 10,040,859

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,040,859

Title:	Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
Abstract:	Compositions and methods for treating a cytokine release syndrome such as chimeric antigen receptor T-cell cytokine release syndrome or hemophagocytic lymphohistiocytosis are provided.
Inventor(s):	Behrens; Edward M. (West Chester, PA), Rood; Julia E. (Philadelphia, PA), Kambayashi; Taku (Malvern, PA)
Assignee:	The Children\'s Hospital of Philadelphia (Philadelphia, PA) The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	15/305,272
Patent Claims:	1. A method for inhibiting or treating a cytokine-related disease or disorder in a subject, said method comprising administering to a subject an IL-33 pathway inhibitor, wherein said cytokine-related disease or disorder is hemophagocytic lymphohistiocytosis, and wherein said IL-33 pathway inhibitor is an antibody or fragment thereof immunologically specific for IL-33 receptor (IL-33R). 2. The method of claim 1, wherein said method further comprises administering a hemophagocytic lymphohistiocytosis therapy selected from the group consisting of an immunosuppressant, glucocorticoid, cyclosporine A, etoposide, methotrexate, IL-1 blocking agent, rilonacept, canakinumab, and gevokizumab. 3. The method of claim 1, wherein said method further comprises performing a bone marrow transplant on said subject. 4. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is familial (primary) hemophagocytic lymphohistiocytosis (FHL). 5. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is secondary hemophagocytic lymphohistiocytosis (SHLH). 6. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is malignancy associated hemophagocytic lymphohistiocytosis. 7. The method of claim 1, wherein said antibody or fragment thereof is immunologically specific for the extracellular domain of IL-33R. 8. The method of claim 1, wherein said method comprises administering an antibody immunologically specific for IL-33R to the subject. 9. The method of claim 1, wherein said method comprises administering an antibody immunologically specific for the extracellular domain of IL-33R to the subject.

Details for Patent 10,040,859

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	02/27/2008	⤷ Try a Trial	2034-04-21
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	06/17/2009	⤷ Try a Trial	2034-04-21
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	12/22/2016	⤷ Try a Trial	2034-04-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.